This company is no longer active
PHAS.Q Stock Overview
A clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiovascular diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
PhaseBio Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.000001 |
| 52 Week High | US$0.0097 |
| 52 Week Low | US$0.000001 |
| Beta | 0 |
| 1 Month Change | 0% |
| 3 Month Change | 0% |
| 1 Year Change | -99.50% |
| 3 Year Change | -100.00% |
| 5 Year Change | -100.00% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
PhaseBio Pharmaceuticals GAAP EPS of -$0.34 misses by $0.03, revenue of $0.21M misses by $0.29M
Aug 12PhaseBio Pharmaceuticals (NASDAQ:PHAS) Has Debt But No Earnings; Should You Worry?
Aug 10
PhaseBio shares surge after inking exclusive license agreement for bentracimab
Jun 17What Kind Of Shareholders Hold The Majority In PhaseBio Pharmaceuticals, Inc.'s (NASDAQ:PHAS) Shares?
Mar 04If You Had Bought PhaseBio Pharmaceuticals' (NASDAQ:PHAS) Shares A Year Ago You Would Be Down 28%
Jan 08PhaseBio Pharmaceuticals EPS misses by $0.15
Nov 12Shareholder Returns
| PHAS.Q | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | -3.1% | -0.9% |
| 1Y | -99.5% | -8.7% | 8.4% |
Return vs Industry: PHAS.Q underperformed the US Biotechs industry which returned 16.5% over the past year.
Return vs Market: PHAS.Q underperformed the US Market which returned 21.7% over the past year.
Price Volatility
| PHAS.Q volatility | |
|---|---|
| PHAS.Q Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 10.9% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: PHAS.Q has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine PHAS.Q's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | n/a | Jonathan Mow | phasebio.com |
PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiovascular diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or an invasive procedure. The company is also developing PB1046, a vasoactive intestinal peptide analogue for the treatment of pulmonary arterial hypertension; and PB6440 for the treatment of resistant hypertension.
PhaseBio Pharmaceuticals, Inc. Fundamentals Summary
| PHAS.Q fundamental statistics | |
|---|---|
| Market cap | US$49.00 |
| Earnings (TTM) | -US$102.84m |
| Revenue (TTM) | US$818.00k |
0.0x
P/S Ratio0.0x
P/E RatioIs PHAS.Q overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PHAS.Q income statement (TTM) | |
|---|---|
| Revenue | US$818.00k |
| Cost of Revenue | US$87.70m |
| Gross Profit | -US$86.88m |
| Other Expenses | US$15.96m |
| Earnings | -US$102.84m |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did PHAS.Q perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/09/12 05:05 |
| End of Day Share Price | 2024/09/12 00:00 |
| Earnings | 2022/06/30 |
| Annual Earnings | 2021/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
PhaseBio Pharmaceuticals, Inc. is covered by 5 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Andrew Fein | H.C. Wainwright & Co. |
| Chad Messer | Needham & Company |
| Annabel Samimy | Stifel, Equities Research |